Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3 …

GV Long, R Dummer, O Hamid, TF Gajewski… - The Lancet …, 2019 - thelancet.com
Background Immunotherapy combination treatments can improve patient outcomes.
Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed …

[HTML][HTML] Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE …

TC Mitchell, O Hamid, DC Smith, TM Bauer… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Tumors may evade immunosurveillance through upregulation of the indoleamine 2,
3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly selective IDO1 enzyme …

First-in-human phase I study of the oral inhibitor of indoleamine 2, 3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies

GL Beatty, PJ O'Dwyer, J Clark, JG Shi… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: Indoleamine 2, 3-dioxygenase-1 (IDO1) catalyzes the degradation of
tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can …

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301 …

GV Long, R Dummer, O Hamid, T Gajewski, C Caglevic… - 2018 - ascopubs.org
108 Background: In a phase 1/2 study, the combination of E, a selective oral inhibitor of the
IDO1 enzyme, plus P, a PD-1 inhibitor, suggested promising antitumor activity with minimal …

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse) …

R Kristeleit, I Davidenko, V Shirinkin, F El-Khouly… - Gynecologic …, 2017 - Elsevier
Abstract Objective Indoleamine 2, 3-dioxygenase-1 (IDO1) is a key regulator of immune
tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme …

[HTML][HTML] Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

GT Gibney, O Hamid, J Lutzky, AJ Olszanski… - … for immunotherapy of …, 2019 - Springer
Background Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2, 3-
dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of …

Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

DC Smith, T Gajewski, O Hamid, JS Wasser… - 2017 - ascopubs.org
4503 Background: Pembrolizumab (P), a PD-1 inhibitor, is active and well tolerated in
platinum-treated, advanced urothelial carcinoma (UC). Epacadostat (E) potently and …

[HTML][HTML] Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

TC Gangadhar, O Hamid, DC Smith, TM Bauer… - … for immunotherapy of …, 2015 - Springer
Background Indoleamine 2, 3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme
that is expressed in many cancers and induces immune tolerance by suppressing T cell …

Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.

GT Gibney, O Hamid, TC Gangadhar, J Lutzky… - 2014 - ascopubs.org
3010 Background: Indoleamine 2, 3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing
enzyme that is overexpressed in cancers and induces immune tolerance by suppressing T …

Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.

AI Spira, O Hamid, TM Bauer, VF Borges, JS Wasser… - 2017 - ascopubs.org
1103 Background: Epacadostat is an oral, potent, and selective inhibitor of indoleamine 2, 3-
dioxygenase 1, a tryptophan-catabolizing enzyme that induces immune tolerance via T-cell …